Table 4

Beers' Criteria for specific PIMs by place of residence

Criteria	At home %	In care %	OR (95% CI)		Severity rating
Criteria	At home %	In care %	Unadjusted	Adjusted^*	Severity rating
Long-acting benzodiazepines	6.36	11.13	1.85 (1.68 to 2.04)	1.62 (1.45 to 1.81)^‡	High
Nitrofurantoin	2.46	5.84	2.46 (2.15 to 2.81)	1.52 (1.30 to 1.76)^‡	High
Fluoxetine	2.10	4.83	2.37 (2.05 to 2.74)	2.25 (1.91 to 2.65)^‡	High
Muscle relaxants	1.69	3.84	2.32 (1.97 to 2.73)	1.42 (1.19 to 1.70)^‡	High
Dipyridamole	1.47	3.75	2.61 (2.21 to 3.08)	1.74 (1.45 to 2.09)^‡	Low
Amitriptyline	7.76	5.99	0.76 (0.67 to 0.86)	0.59 (0.51 to 0.67)^§	High
NSAIDs	3.92	1.56	0.39 (0.31 to 0.49)	0.42 (0.33 to 0.54)^§	High
Gastrointestinal antispasmodic	1.06	0.92	0.87 (0.63 to 1.18)	0.70 (0.51 to 0.98)^§	High
Doxasozin	5.66	2.15	0.37 (0.30 to 0.49)	0.29 (0.24 to 0.36)^§	Low
Cimetidine	0.84	0.48	0.57 (0.37 to 0.88)	0.48 (0.31 to 0.75)^§	Low
Ferrous sulphate^† >325 mg/d	6.61	13.93	1.32 (1.02 to 1.70)	0.76 (0.58 to 1.01)	Low
Anticholinergics/antihistamines	3.34	4.7	1.42 (1.23 to 1.64)	1.05 (0.90 to 1.23)	High
Digoxin^† >125 mg/day	1.60	2.65	1.05 (0.62 to 1.77)	0.74 (0.43 to 1.29)	Low
Amiodarone	0.68	0.88	1.29 (0.93 to 1.79)	0.76 (0.54 to 1.08)	High

↵* Age, sex and polypharmacy were adjusted for in all analyses.
↵† Results extrapolated from patients registered with diabetes.
↵‡ Significantly higher PIM in ‘in care’ patients.
↵§ Significantly higher PIM in ‘at home’ patients.
NSAID, nonsteroidal anti-inflammatory drug; PIM, potentially inappropriate medicine.